Drug
Edralbrutinib clinical trials
Also written SHR1459.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Jiangsu HengRui Medicine Co., Ltd. (9) · Reistone Biopharma Company Limited (1)
Often tested with
Tested in the same studies.
Efavirenz (1) · Itraconazole (1) · Gemcitabine-oxaliplatin regimen (1)
Studies
Open first, then newest update. How each study uses edralbrutinib is read from its arms, and is right about nine times in ten.
Testing it · 10
- Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous NephropathyActive, not recruitingPhase 2Reistone Biopharma Company LimitedNCT05136456Written as SHR1459 Low Dose
- A Trial of DDI Between SHR1459 and Efavirenz With Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05560360Written as SHR1459 tablet
- Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell NeoplasmstumorStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03664297Written as SHR1459
- A Bioavailability Study of SHR1459 on Healthy Chinese VolunteersCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04395053Written as SHR1459
- Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male VolunteersStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05095337Written as [14C]SHR1459
- A Phase I Study of SHR1459 in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04455100Written as SHR1459/Itraconazole
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04948788Written as SHR1459 ；YY-20394
- Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)CompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04649723Written as SHR1459
- A Food Effect Study of SHR1459 on Healthy Chinese Adult SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04291846Written as SHR1459 fasted in P1, high-fat diet in P2
- Safety, Tolerability and PK/PD of SHR1459 in Healthy VolunteersStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03668509Written as SHR1459
Given in every arm · 1 — edralbrutinib is usual care beside what is tested
Codes
What other systems call edralbrutinib · ClinicalTrials.gg INT017909
- UNII (FDA) SG5I5QTR4EEDRALBRUTINIBOne source FDA
- NCI Thesaurus C175775EdralbrutinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SG5I5QTR4E | EDRALBRUTINIB | One source FDA |
| NCI Thesaurus | C175775 | Edralbrutinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.